3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
4
Oligodendroglioma
2
Astrocytoma
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Healthy Adult Participants
1
Disease Attributes
1
Interventions
pralsetinib
2
Paclitaxel
2
vorasidenib
1
ripretinib
1
ribociclib
1
repotrectinib
1
pembrolizumab
1
interferon gamma-1b
1
Pemetrexed
1
Oxaliplatin
1
Oncolytic Virotherapy
1
Ocoxin
1
Interferon-gamma
1
Immunotherapy
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms, Germ Cell and Embryonal
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing